Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 30

recruiting
3 968
countries
28
conditions
2 103

509 trials match your criteria

Chronic graft versus host disease

Not recruiting

Study on Axatilimab and Ruxolitinib for Patients with Newly Diagnosed Chronic Graft-Versus-Host Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab

Dilated cardiomyopathy

Not recruiting

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ab-1002

Fabry's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Pegunigalsidase Alfa for Adults with Fabry Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Pegunigalsidase Alfa

Metachromatic leukodystrophy

Not recruiting

Study of Intrathecal Cebsulfase Alfa for Children with Late Infantile Metachromatic Leukodystrophy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Cebsulfase Alfa

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bay 2927088

Pancreatic carcinoma metastatic

Not recruiting

Study on the Safety and Effectiveness of Mitazalimab with Chemotherapy for Patients with Metastatic Pancreatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate

Haematological malignancy+1

Not recruiting

Study of Elraglusib Alone or with Chemotherapy for Patients with Refractory Blood Cancers or Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Elraglusib

Acute myeloid leukaemia

Not recruiting

Study on WT1 mRNA DC Vaccine to Prevent Relapse in Adults with Acute Myeloid Leukemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Wt1 Mrna Dc

Brain stem glioma+1

Not recruiting

Study of WT1 LAMP mRNA DC Immunotherapy for Children with High-Grade Glioma and Diffuse Intrinsic Pontine Glioma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Wt1 Lamp Mrna Dc

Neoplasm

Not recruiting

Study on WT1/IL15/IL15Ra mRNA DC Vaccine for Patients with Advanced or Refractory Solid Tumors of the Pancreas, Esophagus, Liver, or Ovaries

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Wt1/Il15/Il15Ra Mrna Dc

Pleural mesothelioma malignant

Not recruiting

Study of WT1 LAMP mRNA DC Vaccine for Patients with Malignant Pleural Mesothelioma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Wt1 Lamp Mrna Dc

Glioblastoma

Not recruiting

Study on WT1 LAMP mRNA DC and Temozolomide for Patients with Newly Diagnosed Glioblastoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Wt1 Lamp Mrna Dc

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.